Austin C A, Marsh K L, Wasserman R A, Willmore E, Sayer P J, Wang J C, Fisher L M
Department of Biochemistry and Genetics, Medical School, University, Newcastle-upon-Tyne, United Kingdom.
J Biol Chem. 1995 Jun 30;270(26):15739-46. doi: 10.1074/jbc.270.26.15739.
Human cells express two genetically distinct isoforms of DNA topoisomerase II, alpha and beta, which catalyze ATP-dependent DNA strand passage and are an important antitumor drug target. Here we report for the first time the successful overexpression of human topoisomerase II beta in yeast by cloning a topoisomerase II beta cDNA in a yeast shuttle vector under the control of a galactose-inducible promoter. Recombinant human topoisomerase II beta (residues 46-1621 fused to the first 5 residues of yeast topoisomerase II) was purified to homogeneity, yielding an enzymatically active polypeptide in sufficient quantity to allow analysis of its domain structure and comparison with that of recombinant human topoisomerase II alpha. Partial digestion of beta with either trypsin or protease SV8 generated fragments of approximately 130, 90, 62, and 45-50 kDa, arising from cleavage at three limited and discrete regions of the protein (A, B, and C) indicating the presence of at least four structural domains. Recombinant human topoisomerase II alpha and beta induced DNA breakage which was promoted by a variety of agents. Isoform differences in drug-induced DNA breakage were observed. These studies of human topoisomerase II beta in concert with alpha should aid the determination of their individual roles in cancer chemotherapy and should facilitate the design, targeting, and testing of cytotoxic antitumor agents.
人类细胞表达两种基因不同的DNA拓扑异构酶II亚型,即α和β,它们催化依赖ATP的DNA链通过,是重要的抗肿瘤药物靶点。在此,我们首次报告通过在半乳糖诱导型启动子控制下,将拓扑异构酶IIβ cDNA克隆到酵母穿梭载体中,成功在酵母中过表达人拓扑异构酶IIβ。重组人拓扑异构酶IIβ(与酵母拓扑异构酶II的前5个残基融合的46 - 1621位残基)被纯化至同质,产生了足够量的具有酶活性的多肽,从而能够分析其结构域结构并与重组人拓扑异构酶IIα进行比较。用胰蛋白酶或蛋白酶SV8对β进行部分消化产生了约130、90、62和45 - 50 kDa的片段,这些片段来自蛋白质三个有限且离散区域(A、B和C)的切割,表明至少存在四个结构域。重组人拓扑异构酶IIα和β诱导DNA断裂,多种试剂可促进这种断裂。观察到药物诱导的DNA断裂存在亚型差异。这些关于人拓扑异构酶IIβ与α协同作用的研究应有助于确定它们在癌症化疗中的各自作用,并应促进细胞毒性抗肿瘤药物的设计、靶向和测试。